Kathrin Jansen to Humans
This is a "connection" page, showing publications Kathrin Jansen has written about Humans.
Connection Strength
0.059
-
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 10; 586(7830):589-593.
Score: 0.007
-
The role of vaccines in fighting antimicrobial resistance (AMR). Hum Vaccin Immunother. 2018; 14(9):2142-2149.
Score: 0.006
-
Reevaluation of Positivity Cutoff Values for the Pneumococcal Urinary Antigen Detection Assay. Clin Vaccine Immunol. 2017 11; 24(11).
Score: 0.006
-
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021 08; 596(7871):273-275.
Score: 0.002
-
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021 07 15; 385(3):239-250.
Score: 0.002
-
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021 07; 595(7868):572-577.
Score: 0.002
-
BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. N Engl J Med. 2021 07 29; 385(5):472-474.
Score: 0.002
-
Neutralizing Activity of BNT162b2-Elicited Serum. N Engl J Med. 2021 04 15; 384(15):1466-1468.
Score: 0.002
-
BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021 04; 592(7853):283-289.
Score: 0.002
-
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 12 31; 383(27):2603-2615.
Score: 0.002
-
Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020 12 17; 383(25):2439-2450.
Score: 0.002
-
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature. 2020 10; 586(7830):594-599.
Score: 0.002
-
S. aureus colonization in healthy Australian adults receiving an investigational S. aureus 3-antigen vaccine. J Infect. 2019 12; 79(6):582-592.
Score: 0.002
-
Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults. Vaccine. 2019 09 30; 37(42):6201-6207.
Score: 0.002
-
A phase 1 randomized study assessing safety and immunogenicity of two 3-dose regimens of a Clostridium difficile vaccine in healthy older Japanese adults. Vaccine. 2019 05 01; 37(19):2600-2607.
Score: 0.002
-
Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents. Vaccine. 2019 03 14; 37(12):1710-1719.
Score: 0.002
-
A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in Quebec. mSphere. 2018 12 05; 3(6).
Score: 0.002
-
Two Vaccines for Staphylococcus aureus Induce a B-Cell-Mediated Immune Response. mSphere. 2018 08 22; 3(4).
Score: 0.002
-
Evaluation of a Validated Luminex-Based Multiplex Immunoassay for Measuring Immunoglobulin G Antibodies in Serum to Pneumococcal Capsular Polysaccharides. mSphere. 2018 08 08; 3(4).
Score: 0.002
-
Development and Validation of 13-plex Luminex-Based Assay for Measuring Human Serum Antibodies to Streptococcus pneumoniae Capsular Polysaccharides. mSphere. 2018 08 08; 3(4).
Score: 0.002
-
From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine. Expert Rev Vaccines. 2018 06; 17(6):461-477.
Score: 0.002
-
Vaccination strategies for the prevention of meningococcal disease. Hum Vaccin Immunother. 2018 05 04; 14(5):1203-1215.
Score: 0.002
-
A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults. N Engl J Med. 2017 12 14; 377(24):2349-2362.
Score: 0.001
-
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial. Vaccine. 2017 05 31; 35(24):3256-3263.
Score: 0.001
-
Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France. Vaccine. 2017 03 13; 35(11):1530-1537.
Score: 0.001
-
SA4Ag, a 4-antigen Staphylococcus aureus vaccine, rapidly induces high levels of bacteria-killing antibodies. Vaccine. 2017 02 22; 35(8):1132-1139.
Score: 0.001
-
A randomized, controlled, phase 1/2 trial of a Neisseria meningitidis serogroup B bivalent rLP2086 vaccine in healthy children and adolescents. Pediatr Infect Dis J. 2013 Apr; 32(4):364-71.
Score: 0.001